Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Third Arc Bio teams up with Adagene to create T-cell engagers
Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers.
Gabrielle Masson
Nov 13, 2025 10:45am
Neurocrine-Takeda psychiatry pact suffers another phase 2 fail
Nov 11, 2025 6:25am
Voyager sets sail on neuro research trek with Transition Bio
Nov 10, 2025 5:23pm
Lyell signs deal for phase 1-stage colorectal cancer CAR-T
Nov 10, 2025 9:45am
Lilly bags eye-catching gene therapy in $475M deal
Nov 10, 2025 7:00am
Lilly pens $1.2B pact with Sanegene to target metabolic RNA meds
Nov 10, 2025 4:05am
